Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.
about
Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infectionInfluenza vaccination in HIV-positive subjects: latest evidence and future perspectiveEffect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccineAn update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccineHIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected childrenThe pandemic influenza A (H1N1) 2009 vaccine does not increase the mortality rate of idiopathic interstitial pneumonia: a matched case-control study.Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients.A pilot study showing differences in glycosylation patterns of IgG subclasses induced by pneumococcal, meningococcal, and two types of influenza vaccines.Seasonal influenza vaccination of high-risk adults.High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults.H1N1pdm09 adjuvanted vaccination in HIV-infected adults: a randomized trial of two single versus two double doses.Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients.Immune response to 2009 H1N1 vaccine in HIV-infected adults in Northern Thailand.Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals.Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women.Lower Baseline Germinal Center Activity and Preserved Th1 Immunity Are Associated With Hepatitis B Vaccine Response in Treated HIV Infection.Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls.Vaccination of HIV-infected pregnant women: implications for protection of their young infants.Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore.British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015.Immunization of HIV-infected adult patients - French recommendations.Vaccine approaches conferring cross-protection against influenza viruses.
P2860
Q24193121-E9C0FA60-8FC6-4535-BF85-3585F93D3DFEQ27007483-780990C0-DF5B-4EE5-A268-630B7D2F5D97Q28728791-456D248A-98CA-414F-99D0-422716D9D768Q30352329-916EFD4A-C151-4CDF-81BB-99898356CF84Q30353329-0251F093-B857-4028-8424-D24E1C29A4FDQ30359207-221939A7-2485-41A7-8FDB-5AFE4CE990C9Q30359671-0D3AF8CC-662D-4AA7-A953-D2B8D0442708Q30364472-BB354547-3F1D-4123-B3D9-08E6A785468CQ30368704-061E11AA-2230-4AFE-9A43-0CBA6D23AECAQ30387979-5A1D8B35-DF88-4A3A-AC93-CD4F9E5B0012Q30412595-C268AF54-38BA-45AA-A6C6-DB99C98FEB22Q30418834-87B92E90-F0DC-4A1A-AB08-84E350656B6AQ30419842-3434950A-DA26-4C66-A969-D5637E7DEA09Q30420230-63D2655A-B794-44D8-857C-FD03114511B6Q30420476-21C4CE51-7FC0-4634-A33D-88EE25A831E1Q30420821-D74183DF-04F1-4020-976A-7F6E3FBA645BQ30426754-60194D02-1C52-4258-98B1-96E5B65DBBA3Q33745613-F48AB3EA-E504-45C9-9593-9CC1429D9E2AQ38036063-D886DF5E-F213-44BA-88D6-74891870B656Q38446730-F7C5B447-BDFD-427E-BFCD-FE4799B6A45CQ40051928-5DEB47DD-FAC4-480E-A9AC-B8C592686D6AQ40300395-D6848979-BB9D-4C4D-B8A6-ED7D7487742EQ40560650-9CCD3FFE-616B-4E8C-9582-E483507F440CQ40615516-2A90794F-8C26-41BE-AEB9-7268CA564BA0Q41934895-95DAD6E9-09AA-478C-8598-9172496E5C65
P2860
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Safety and immunogenicity of a ...... randomized, controlled trial.
@ast
Safety and immunogenicity of a ...... randomized, controlled trial.
@en
type
label
Safety and immunogenicity of a ...... randomized, controlled trial.
@ast
Safety and immunogenicity of a ...... randomized, controlled trial.
@en
prefLabel
Safety and immunogenicity of a ...... randomized, controlled trial.
@ast
Safety and immunogenicity of a ...... randomized, controlled trial.
@en
P2093
P2860
P356
P1476
Safety and immunogenicity of a ...... randomized, controlled trial.
@en
P2093
ANRS 151 HIFLUVAC Study Group ...... inique en Vaccinologie REIVAC)
Christine Durier
Christine Jacomet
Corinne Desaint
Faiza Ajana
François Raffi
François Roman
Gilles Pialoux
Jacques Reynes
P2860
P304
P356
10.1093/INFDIS/JIR211
P407
P577
2011-07-01T00:00:00Z